Trinity Biotech (TRIB) Reaches New 52-Week Low at $3.77

Share on StockTwits

Trinity Biotech plc (NASDAQ:TRIB)’s share price hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as $3.77 and last traded at $3.84, with a volume of 400 shares changing hands. The stock had previously closed at $3.80.

Separately, ValuEngine upgraded Trinity Biotech from a “hold” rating to a “buy” rating in a research note on Wednesday, July 11th.

The company has a quick ratio of 3.55, a current ratio of 5.23 and a debt-to-equity ratio of 1.43. The company has a market cap of $79.74 million, a PE ratio of 23.81 and a beta of 1.12.

Trinity Biotech (NASDAQ:TRIB) last issued its quarterly earnings results on Thursday, July 19th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($0.03). Trinity Biotech had a negative net margin of 41.88% and a positive return on equity of 3.59%. The firm had revenue of $25.00 million for the quarter.

A number of institutional investors and hedge funds have recently modified their holdings of TRIB. Deutsche Bank AG increased its stake in Trinity Biotech by 3,969,200.0% during the fourth quarter. Deutsche Bank AG now owns 39,693 shares of the company’s stock valued at $202,000 after acquiring an additional 39,692 shares during the period. Renaissance Technologies LLC increased its stake in Trinity Biotech by 18.8% during the second quarter. Renaissance Technologies LLC now owns 547,865 shares of the company’s stock valued at $2,739,000 after acquiring an additional 86,815 shares during the period. Hunter Associates Investment Management LLC increased its stake in Trinity Biotech by 3.6% during the second quarter. Hunter Associates Investment Management LLC now owns 774,258 shares of the company’s stock valued at $3,871,000 after acquiring an additional 26,777 shares during the period. 22NW LP increased its stake in Trinity Biotech by 1.2% during the second quarter. 22NW LP now owns 953,728 shares of the company’s stock valued at $4,769,000 after acquiring an additional 11,501 shares during the period. Finally, First Wilshire Securities Management Inc. increased its stake in Trinity Biotech by 3.0% during the second quarter. First Wilshire Securities Management Inc. now owns 1,030,805 shares of the company’s stock valued at $5,154,000 after acquiring an additional 29,931 shares during the period. Hedge funds and other institutional investors own 69.70% of the company’s stock.

About Trinity Biotech (NASDAQ:TRIB)

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease, sexually transmitted diseases, respiratory infections, epstein barr virus, and other viral pathogens; and products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a high risk of developing diabetes.

Read More: Investing in Growth Stocks

Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply